XEGLYZE Drug Patent Profile

When do Xeglyze patents expire, and what generic alternatives are available?

Xeglyze is a drug marketed by Lnhc and is included in one NDA. There are two patents protecting this drug.

This drug has thirty-six patent family members in fifteen countries.

The generic ingredient in XEGLYZE is abametapir. Additional details are available on the abametapir profile page.

DrugPatentWatch^® Generic Entry Outlook for Xeglyze

Xeglyze was eligible for patent challenges on July 31, 2024.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be October 28, 2026. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for XEGLYZE

International Patents:	36
US Patents:	2
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	112
Patent Applications:	363
What excipients (inactive ingredients) are in XEGLYZE?	XEGLYZE excipients list
DailyMed Link:	XEGLYZE at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for XEGLYZE

NDA:

206966

Dosage:

LOTION;TOPICAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for XEGLYZE

XEGLYZE is protected by two US patents.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Lnhc	XEGLYZE	abametapir	LOTION;TOPICAL	206966-001	Jul 24, 2020		DISCN	Yes	No			Y
Lnhc	XEGLYZE	abametapir	LOTION;TOPICAL	206966-001	Jul 24, 2020		DISCN	Yes	No			Y

Expired US Patents for XEGLYZE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Lnhc	XEGLYZE	abametapir	LOTION;TOPICAL	206966-001	Jul 24, 2020
Lnhc	XEGLYZE	abametapir	LOTION;TOPICAL	206966-001	Jul 24, 2020
Lnhc	XEGLYZE	abametapir	LOTION;TOPICAL	206966-001	Jul 24, 2020

International Patents for XEGLYZE

See the table below for patents covering XEGLYZE around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2014377875	Pediculicidal composition
Canada	2933081	COMPOSITION PEDICULICIDE (PEDICULICIDAL COMPOSITION)
Eurasian Patent Organization	031732	ПЕДИКУЛИЦИДНАЯ КОМПОЗИЦИЯ (PEDICULICIDAL COMPOSITION)
Eurasian Patent Organization	201691033	ПЕДИКУЛИЦИДНАЯ КОМПОЗИЦИЯ (PEDICULICIDAL COMPOSITION)
European Patent Office	3082424	COMPOSITION PEDICULICIDE (PEDICULICIDAL COMPOSITION)
Spain	2967618
Japan	2017500342	シラミ駆除組成物

Xeglyze market dynamics and financial trajectory: sales momentum, payer access, and exclusivity-driven generic risk

Last updated: July 29, 2026

Xeglyze is marketed as a prescription pharmaceutical product, but no complete, reliably citeable set of commercial and IP-regulatory details is available in the information provided in this chat. Under these constraints, a complete and accurate market dynamics and financial trajectory assessment cannot be produced.

What is Xeglyze’s current FDA status and Orange Book standing?

Featured-snippet answer: No verifiable FDA approval details, NDA/BLA number, application holder, or Orange Book listing data for Xeglyze are available in the provided material, so its regulatory status and exclusivity mechanics cannot be stated.

Which FDA application (NDA/BLA) is Xeglyze under, and what is its approval date?

No approval date, application type, or applicant/holder details for Xeglyze are present in the provided material.

What exclusivities apply (223, 24-month, 5-year, pediatric), and when do they expire?

No exclusivity codes or end dates for Xeglyze are provided.

Is Xeglyze listed in the Orange Book, and what patents are tied to the approval?

No Orange Book patent list for Xeglyze is included in the provided material.

---

How fast is Xeglyze penetrating the market: who are its launch customers and distribution channels?

Featured-snippet answer: Launch-year prescriber adoption, pharmacy channel mix, wholesaler coverage, and key account uptake for Xeglyze are not available from the provided material.

Which payer segments are driving adoption: commercial, Medicare, Medicaid?

No formulary or coverage data for Xeglyze is included.

What utilization management applies (prior authorization, step edits, quantity limits)?

No PA, step-therapy, or limit details are provided.

Is Xeglyze bought through specialty pharmacies, retail channels, or buy-and-bill?

No channel strategy or dispensing model for Xeglyze is included.

---

What do revenue and unit sales look like for Xeglyze across years?

Featured-snippet answer: Sales trajectory, net revenue, prescription counts, and growth rates for Xeglyze are not provided, and no revenue reporting links or financial statement excerpts appear in the supplied material.

What is Xeglyze’s financial trajectory: launch peak, trendline, and drawdown risk?

No historical revenue or prescription dataset is present in the provided material.

What is the relationship between pricing and volume for Xeglyze?

No ASP/WAC, rebating, or net price data is present.

How concentrated is revenue: top payers, IDNs, and regional exposure?

No payer or geographic concentration data is provided.

---

Which business drivers are most likely shaping Xeglyze’s market dynamics?

Featured-snippet answer: No clinical differentiator, guideline position, safety/tolerability profile, or competitive comparator data for Xeglyze is present in the provided material.

Does Xeglyze have a differentiated mechanism-of-action or label expansion driving demand?

No mechanism-of-action or label details are included.

What competitor class pressures exist (same indication alternatives, class efficacy, safety, and access)?

No competitor list or comparative market data is provided.

How do safety signals, REMS, or post-marketing requirements impact access and prescribing?

No REMS or post-marketing surveillance details are provided.

---

What patents protect Xeglyze and how do they affect financial durability?

Featured-snippet answer: Patent coverage, expiration dates, and exclusivity barriers for Xeglyze are not provided, so financial durability under IP protection cannot be quantified.

Which Orange Book patents cover Xeglyze (active ingredient, formulation, method-of-use, device/system)?

No Orange Book patent numbers or claims are provided.

When does Xeglyze lose exclusivity: non-patent exclusivity vs patent-by-patent expiry?

No exclusivity or patent expiry timelines are included.

Is there Paragraph IV generic pressure or biosimilar risk?

No ANDA/BLA challenge data for Xeglyze is present.

---

How does Xeglyze compare with competing drugs on access and market share?

Featured-snippet answer: No competitive set, market share data, or payer access comparisons for Xeglyze are provided.

What is the competitive landscape in the therapeutic area?

No therapeutic area, comparators, or class dynamics are included.

Which rival products have stronger formulary placement or lower net cost?

No formulary positioning or net price comparisons are provided.

---

What generic entry risks exist for Xeglyze, and what would a launch scenario look like?

Featured-snippet answer: Without patent expiration dates, Orange Book “listed” patents, and challenge records, a launch scenario cannot be constructed.

What is the earliest plausible generic filing and approval window?

No ANDA filing/approval data is provided.

What is the expected impact of entry on pricing and revenue?

No historical analogs (similar molecule entry patterns) are provided.

Could authorized generics or settlement agreements delay entry?

No settlement data or authorized generic strategy is included.

---

Key Takeaways

• A complete market dynamics and financial trajectory for Xeglyze cannot be produced from the information available in this chat.
• Regulatory status (FDA application, approval date, Orange Book listings) and IP status (patents, exclusivity, expiration dates, challenges) are not available here.
• Sales trajectory (revenue, units, prescriptions), payer access, channel mix, and competitive comparisons are not available here.
• No defensible claims about market momentum, downside risks, or generic entry timing can be made without citeable underlying data.

---

FAQs

1. Is Xeglyze a branded product only, or are there authorized generics already available?
2. Does Xeglyze have any REMS requirements that restrict prescribing or dispensing?
3. What payer policies most influence Xeglyze uptake (prior authorization, step therapy, non-formulary status)?
4. Are there any known ANDA Paragraph IV challenges targeting Xeglyze’s Orange Book patents?
5. What is Xeglyze’s pricing structure and how does it translate into net revenue versus gross sales?

---

References

1. (No citeable sources were provided in the prompt.)